Pharma Test E 250 mg — Pharmacom Labs

Description

Pharma Test E 250 mg Pharmacom Labs — testosterone enanthate from Pharmacom Labs, formulated at 250 mg per unit. The seven-day half-life makes this the workhorse ester for any classic cycle base: once- or twice-weekly injections maintain stable serum testosterone across 12–16 week protocols. TRT maintenance, performance bulking, or lean-gaining stacks all start here.

Key Benefits

The textbook cycle base — more published research than any other AAS
Seven-day ester allows twice-weekly or weekly injections
Predictable serum curves — dose → expected plasma level is linear
Aromatises — full oestrogenic spectrum requires AI management
Foundation for nearly every stack: mass, cutting, recomp, bridge
Each unit dosed at 250 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: TRT 100–200 mg/week; first cycle 400–500 mg/week; intermediate 500–600 mg/week; advanced 700+ mg/week. Above 800 mg/week diminishing anabolic returns with sharply rising sides. Split across 2 injections (Mon/Thu) for stable plasma.

How It Works

Testosterone esterified to enanthoic acid. Plasma esterases hydrolyse the bond, releasing free testosterone that activates the AR across muscle, bone, and CNS. Downstream: nitrogen retention, protein synthesis, elevated IGF-1 (hepatic and intramuscular), increased RBC output, HPTA suppression.

Pharmacokinetics

Plasma half-life approximately 7 days. Once-weekly pinning produces a measurable peak-to-trough swing; twice-weekly (Mon/Thu split) smooths plasma testosterone to within ~30% of the daily average. Steady-state reached at week 4–5.

Potential Side Effects

Oestrogenic effects from aromatisation (gyno risk, water retention, BP elevation) manageable with anastrozole 0.25–0.5 mg EOD dosed by bloodwork. Androgenic effects (skin, hair) genotype-dependent. HPTA suppression universal — full PCT non-negotiable. HDL typically drops 20–30%.

Cycle & Stacking Guide

Foundation compound: 12–16 weeks at 400–500 mg/week for beginners; add secondary anabolics per goal (deca/anadrol for mass, primobolan/boldenone for lean-gain, trenbolone/masteron for cutting). PCT (Nolva+Clomid) begins 14 days after last injection.

Manufacturer Notes

Pharmacom Labs operates from EU-registered facilities with in-house HPLC verification. Every batch ships with a unique code on the label — scannable at pharmacom-labs.com to confirm authenticity before the vial ever leaves the box.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Pharma Test E 250 mg Pharmacom Labs”

2D structural representation · PubChem CID 9416 ↗

Chemical Identity
#	CAS Registry Number	`315-37-7`
Σ	IUPAC Name	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] heptanoate
F	Molecular Formula	C₂₆H₄₀O₃
M	Molecular Weight	400.60 g/mol
⌬	SMILES	`CCCCCCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`SEM27OEN34OSRR-ZHDKGOKVSA-N`
△	Melting Point	34-39 °C
≋	Solubility	Practically insoluble in water; soluble in vegetable oils
t½	Biological Half-life	4.5 days (IM)
⊕	PubChem CID	9416 ↗

Pharmacological Profile
Anabolic Rating	100
Androgenic Rating	100
Aromatization	Moderate
Hepatotoxicity	None
Detection Time	3 months

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

The 7-carbon heptanoate ester of endogenous testosterone. IM depot kinetics: serum peak at 24–48 h post-injection, steady-state reached after 4–5 half-lives (weeks 3–4). Once-weekly administration produces ~200 ng/dL peak-to-trough variance at 200 mg/week; trough suppression on EOD or twice-weekly splits. Aromatises via CYP19A1 at physiological rates — 0.2–0.3% substrate conversion to estradiol. Target serum E2 on protocol: 25–40 pg/mL (sensitive LC-MS/MS). Aggressive AI dosing that suppresses E2 below 20 pg/mL produces the documented side profile of arthralgia, libido loss, lipid degradation, and cognitive fog — iatrogenic hypoestrogenaemia is a bigger problem than measured hyperoestrogenaemia in most protocols. HPTA shutdown is total within 14 days and predictable; recovery timeline post-cessation is 3–6 months with SERM-based PCT, longer without. Haematocrit drift is the most consistent long-run biomarker — 3–5 percentage points per cycle, additive across cycles without donation.

Known trade names: Delatestryl, Testoviron Depot, Cidoteston

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

Pharma Test E 250 mg Pharmacom Labs